Fractyl - GUTS Quarterly EPS earnings growth

Fractyl Health, Inc - graphic logo of issuer GUTS

Fixed investments in bowel modification equipment establish the foundation for a future monopoly for Fractyl Health, Inc. (GUTS). The quarterly EPS change level visualizes this financial dynamic, where 86.80 serves as the final level marker. The innovative Revita method eliminates the causes of obesity, while streamlined cold chain supplies for biomaterials ensure the stability of the company's operational processes.

Fractyl Health (GUTS) - Year-over-year earnings per share growth for the last twelve months from 02/21/2024 to 11/15/2026

Financial and market metric breakdowns for Fractyl Health, Inc. (GUTS)

- share price and consensus valuation forecast:
Stock Quotes Fractyl Health|GUTS - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Fractyl Health, Inc|GUTS - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Fractyl Health|GUTS - Company Book Value|Market Value to Book Value Ratio fractyl.com|GUTS - Company Assets
- debt and liquidity data:
Debt to Equity Fractyl Health, Inc.|GUTS - Long-Term Debt to Equity|Short-Term Debt to Capital Fractyl Health Inc.|GUTS - Company Total Debt Obligations|Debt to Book Capitalization Ratio Fractyl Health Inc.|GUTS - Long-Term Debt Volume|Company Short-Term Debt Fractyl Health|Quick Ratio fractyl.com
- earnings and valuation multiples indicators:
GUTS - Profit After Tax|Expected Profit Fractyl Health, Inc.|GUTS - Company Value to Net Income|Forward P/E Multiple Fractyl Health, Inc|GUTS - PEG Multiple|EV/EBITDA Multiple Fractyl Health, Inc.|GUTS - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Fractyl Health|GUTS - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months fractyl.com|GUTS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Fractyl Health, Inc.
- sales volume and revenue information:
GUTS - Company Revenue|Company Future Sales Volume Fractyl|GUTS - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Fractyl Health, Inc.
Analysis of all company metrics:Fractyl Health, Inc.
Manufactured product of Fractyl Health, Inc

To protect capital from market volatility, it is critical for investors to track real business performance. The quarterly EPS growth vector reflects the dynamics of net income per share adjusted for taxes, allowing for an assessment of the financial return from the development of innovative diabetes and obesity therapies by Fractyl Health (GUTS), thereby determining the asset's stability within a portfolio.

Competitors of Fractyl Health, Inc. (GUTS)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Biomea Fusion Inc|Year-over-year earnings per share growth for the last 12 months QNCX (Quince Therapeutics)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS